Vaginal progesterone to prevent preterm delivery among HIV-infected pregnant women in Zambia: A feasibility study

Joan T Price, Winifreda M Phiri, Bethany L Freeman, Bellington Vwalika, Jennifer Winston, Chileshe M Mabula-Bwalya, Helen B Mulenga and Jeffrey S A Stringer

PLOS ONE, 2020, vol. 15, issue 1, 1-14

Abstract: Antenatal vaginal progesterone (VP) reduces the risk of preterm birth (PTB) in women with shortened cervical length, and we hypothesize that it may also prevent PTB in women with HIV as their primary risk factor. We conducted a pilot feasibility study in Lusaka, Zambia to investigate uptake, adherence, and retention in preparation for a future efficacy trial. This was a double-masked, placebo-controlled, randomized trial of 200mg daily self-administered VP suppository or placebo. Pregnant women with HIV who were initiating or continuing antiretroviral therapy were eligible for participation. Potential participants underwent ultrasound to assess eligibility; we excluded those ≥24 gestational weeks, with non-viable, multiple gestation, or extrauterine pregnancies, with short cervix (

Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0224874 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 24874&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0224874

DOI: 10.1371/journal.pone.0224874

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().